The implementation of the IRA is currently subject to ongoing litigation that challenges the constitutionality of the IRA’s Medicare drug price negotiation program. The full impact of the IRA on our business and the pharmaceutical and healthcare industry in general is not yet known.
All entries for: Bicara Therapeutics Inc.
March 30, 2026
Bicara Therapeutics Inc.
Neutral Outlook
Boston, MA
1-50 employees
The implementation of the IRA is currently subject to ongoing litigation that challenges the constitutionality of the IRA’s Medicare drug price negotiation program. The full impact of the IRA on our business and the pharmaceutical and healthcare industry in general is not yet known.
Disease Area: Oncology
Drug Type: Biologic
August 12, 2025
Bicara Therapeutics Inc.
Negative Outlook
Boston, MA
1-50 employees
The Inflation Reduction Act of 2022 (the “IRA”) includes several provisions that will impact our business to varying degrees, including provisions that allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, among others.
Disease Area: Oncology
Drug Type: Biologic